Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Gert De Meerleer"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Wouter Everaerts, Steven Joniau, Daimantas Milonas, Lisa Moris, Gert De Meerleer, Thomas Gevaert, Marcella Baldewijns, Gaëtan Devos, Frank Claessens, Hendrik Van Poppel, Charlien Berghen, Wout Devlies
Publikováno v:
Nature reviews. Urology. 18(12)
Patients with high-risk prostate cancer treated with curative intent are at an increased risk of biochemical recurrence, metastatic progression and cancer-related death compared with patients treated for low-risk or intermediate-risk disease. Thus, t
Autor:
Wouter Everaerts, Niloefar Ahmadi Bidakhvidi, Cindy Mai, Charlien Berghen, Gert De Meerleer, Karin Haustermans, Koen Van Laere, Karolien Goffin, Annouschka Laenen, Sander Jentjens, Steven Joniau, Christophe Deroose, Liesbeth De Wever
Publikováno v:
EJNMMI Research
EJNMMI Research, Vol 11, Iss 1, Pp 1-10 (2021)
EJNMMI Research, Vol 11, Iss 1, Pp 1-10 (2021)
Background Detection of the site of recurrence using PSMA-PET/CT is important to guide treatment in patients with biochemical recurrence of prostate cancer (PCa). The aim of this study was to evaluate the positivity rate of [18F]PSMA-1007-PET/CT in p
Autor:
Karel Decaestecker, Kato Rans, Julia Murray, Steven Joniau, Gert De Meerleer, Charlien Berghen, Anne M Leliveld, Christof Vulsteke, Cesare Cozzarini, Valérie Fonteyne, Alberto Bossi, Alberto Briganti, Olivier De Hertogh
Publikováno v:
The Lancet. Oncology. 22(8)
In patients with prostate cancer who have a high risk of pelvic nodal disease, the use of elective whole pelvis radiotherapy is still controversial. Two large, randomised, controlled trials (RTOG 9413 and GETUG-01) did not show a benefit of elective
Autor:
Daimantas Milonas, Kristina Zviniene, Clement Orczyk, Gaëtan Devos, Charlien Berghen, Gert De Meerleer, Alberto Bossi, Hein Van Poppel, Steven Joniau, Wouter Everaerts
Publikováno v:
Salvage Therapy for Prostate Cancer ISBN: 9783030571801
In the setting of locally recurrent prostate cancer (PCa) after primary radiotherapy (RT), the standard of care now used is palliative androgen deprivation therapy (ADT), which is associated with harmful side effects and no clear survival benefit. Th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4e69b0e11880c1228b60c67d8910c80a
https://doi.org/10.1007/978-3-030-57181-8_16
https://doi.org/10.1007/978-3-030-57181-8_16
Autor:
Karolien Goffin, Gaëtan Devos, Kato Rans, Gert De Meerleer, Karin Haustermans, Steven Joniau, Charlien Berghen, Annouschka Laenen
Publikováno v:
Future oncology (London, England). 16(27)
Radical prostatectomy is a well-established treatment option in the management of localized and locally advanced prostate cancer. An extended lymphadenectomy is performed in case of substantial risk for lymph node involvement. When biochemical recurr
Autor:
Piet Ost, Gert De Meerleer, Karel Decaestecker, Elise De Bleser, Lieven Annemans, Renée Bultijnck, Steven Joniau, Filip Ameye, Valérie Fonteyne, Aurélie De Bruycker, Ruben Willems, Ignace Billiet, Nicolaas Lumen
Publikováno v:
Cancers, Vol 12, Iss 1, p 132 (2020)
CANCERS
Cancers
Volume 12
Issue 1
CANCERS
Cancers
Volume 12
Issue 1
The optimal management of patients with oligorecurrent prostate cancer (PCa) is unknown. There is growing interest in metastasis-directed therapy (MDT) for this population. The objective was to assess cost-utility from a Belgian healthcare payer&rsqu
Autor:
Steven Joniau, Gert De Meerleer, Karin Haustermans, Piet Ost, Gaëtan Devos, Kenneth Poels, Charlien Berghen, Karel Decaestecker, Wouter Everaerts
In metastatic castration-refractory prostate cancer (mCRPC), state-of-the-art treatment consists of androgen biosynthesis inhibition (abiraterone), inhibition of the androgen receptor (enzalutamide), chemotherapy, or radium-223 in combination with an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3dbb709a32ae87646c5060b46810f198
https://lirias.kuleuven.be/handle/123456789/645134
https://lirias.kuleuven.be/handle/123456789/645134
Autor:
Gaëtan Devos, Tim Muilwijk, Yannic Raskin, Victor Calderon, Lisa Moris, Thomas Van den Broeck, Charlien Berghen, Gert De Meerleer, Maarten Albersen, Hendrik Van Poppel, Wouter Everaerts, Steven Joniau
Publikováno v:
Frontiers in Oncology
Frontiers in Oncology, Vol 9 (2019)
Frontiers in Oncology, Vol 9 (2019)
Introduction: Salvage lymph node dissection (sLND) has been proposed as a treatment option for prostate cancer patients with lymph node (LN) recurrence following radical prostatectomy to delay or avoid palliative androgen deprivation therapy (ADT). H
Autor:
Nicolaas Lumen, Bert Dhondt, Pieter De Visschere, Bart De Troyer, Gert De Meerleer, Karel Decaestecker, Tom Claeys, Filip Poelaert, Piet Ost, Valérie Fonteyne
Publikováno v:
Strahlentherapie und Onkologie. 193:444-451
The goal of this work was to investigate the oncological outcome of whole pelvis radiotherapy (wpRT) in pathologic pelvic lymph node-positive (pN1) prostate cancer (PCa), evaluate the location of relapse, and identify potential prognostic factors. Al